- Home
- RDZN vs IMMX Comparison
RDZN vs IMMX Comparison
Compare RDZN & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDZN
- IMMX
- Stock Information
- Founded
- RDZN 2015
- IMMX 2014
- Country
- RDZN United States
- IMMX United States
- Employees
- RDZN N/A
- IMMX N/A
- Industry
- RDZN Blank Checks
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- RDZN Finance
- IMMX Health Care
- Exchange
- RDZN Nasdaq
- IMMX Nasdaq
- Market Cap
- RDZN 54.8M
- IMMX 46.8M
- IPO Year
- RDZN N/A
- IMMX 2021
- Fundamental
- Price
- RDZN $1.52
- IMMX $2.28
- Analyst Decision
- RDZN Strong Buy
- IMMX Strong Buy
- Analyst Count
- RDZN 2
- IMMX 1
- Target Price
- RDZN $5.00
- IMMX $7.00
- AVG Volume (30 Days)
- RDZN 682.5K
- IMMX 274.3K
- Earning Date
- RDZN 02-10-2025
- IMMX 11-12-2024
- Dividend Yield
- RDZN N/A
- IMMX N/A
- EPS Growth
- RDZN N/A
- IMMX N/A
- EPS
- RDZN N/A
- IMMX N/A
- Revenue
- RDZN $46,448,411.00
- IMMX N/A
- Revenue This Year
- RDZN $4.38
- IMMX N/A
- Revenue Next Year
- RDZN $61.53
- IMMX $200.00
- P/E Ratio
- RDZN N/A
- IMMX N/A
- Revenue Growth
- RDZN 57.97
- IMMX N/A
- 52 Week Low
- RDZN $0.71
- IMMX $1.26
- 52 Week High
- RDZN $7.17
- IMMX $7.50
- Technical
- Relative Strength Index (RSI)
- RDZN 55.26
- IMMX 56.24
- Support Level
- RDZN $1.18
- IMMX $1.88
- Resistance Level
- RDZN $2.87
- IMMX $2.33
- Average True Range (ATR)
- RDZN 0.43
- IMMX 0.29
- MACD
- RDZN -0.01
- IMMX -0.02
- Stochastic Oscillator
- RDZN 34.84
- IMMX 44.58
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.